At this stage, the primary goal is to allow the body to adjust to the medication and minimise gastrointestinal side effects
Some patients with established cardiovascular disease and overweight or obesity may be candidates for GLP-1 therapy, but this requires medical evaluation
Their use has expanded considerably, and with increased prescribing comes greater awareness of potential adverse effects, including questions about their impact on vision
Month-over-month anti-diabetic medication (ADM) prescribing increased in April and May 2024 then decreased slightly in June 2024
Can you show, for every sterile product lot youve released in the last 12 months, that final sterility and potency results were received and reviewed before the product reached a patient Again, this firm had an at risk release provision that the FDA found functionally meaningless because there was no documented follow-through
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists
